Immune Signatures Combined With BRCA1-Associated Protein 1 Mutations Predict Prognosis and Immunotherapy Efficacy in Clear Cell Renal Cell Carcinoma

• DOI: 10.3389/fcell.2021.747985
• Publication Date: 2021-10-19T21:32:49Z
• Authors: Ze Gao; Junxiu Chen; Yiran Tao; Qiong Wang; Shirong Peng; Shunli Yu; Jianwen Zeng; Kaiwen Li; Zhongqiu Xie; Hai Huang
• Keywords: Univariate analysis

Immunotherapy is gradually emerging in the field of tumor treatment. However, because complexity microenvironment (TME), some patients cannot benefit from immunotherapy. Therefore, we comprehensively analyzed TME and gene mutations ccRCC to identify a comprehensive index that could more accurately guide immunotherapy with ccRCC. We divided into two groups based on immune infiltration activity. Next, investigated differentially expressed genes (DEGs) constructed prognostic score using univariate Cox regression analysis, unsupervised cluster principal component analysis (PCA) validated its predictive power both internal total sets. Subsequently, were investigated, suitable for selected combination score. The prognosis score-low group was significantly worse than score-high group. BRCA1-associated protein 1 (BAP1) mutation had poor prognosis. Thus, this study indicated establishing an model combined BAP1 can better predict patients, screen immunotherapy, select appropriate drug combinations.